Yukiko Ishikawa-Takemura

Author

Kissei Pharmaceutical (Japan)

Also Known As

Yukiko Ishikawa-Takemura

Publications

437

Citations

H-Index

Concepts

All Affiliations

Kissei Pharmaceutical (Japan)Tokyo University of Science

About

Yukiko Ishikawa-Takemura is an author at Kissei Pharmaceutical (Japan) specializing in pharmacology, medicine, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	137
2	Biochemistry	4	4	137
3	Diabetes	3	3	122
4	Health Sciences	2	2	103
5	Natural Sciences	1	1	15

Yukiko Ishikawa-Takemura

Publications

437

Citations

H-Index

Page 1

	Year	Citations
Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models Yoshikazu Fujimori, Kenji Katsuno, Ikumi Nakashima, Journal of Pharmacology and Experimental Therapeutics	2008	219
KGA-2727, a Novel Selective Inhibitor of a High-Affinity Sodium Glucose Cotransporter (SGLT1), Exhibits Antidiabetic Efficacy in Rodent Models Toshihide Shibazaki, Masaki Tomae, Yukiko Ishikawa-Takemura, Journal of Pharmacology and Experimental Therapeutics	2012	81
Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats Yoshikazu Fujimori, Kenji Katsuno, Kazuma Ojima, European Journal of Pharmacology Metabolic SyndromeDiabetes ManagementSelective Sglt2 InhibitorBiochemistryMedicine	2009	70
Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-Ay mice Kenji Katsuno, Yoshikazu Fujimori, Yukiko Ishikawa-Takemura, European Journal of Pharmacology Metabolic SyndromeDiabetes ManagementBiochemistryMedicineInsulin Management	2009	33
Structure–activity relationship studies of 4-benzyl-1H-pyrazol-3-yl β-d-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia Nobuhiko Fushimi, Hideki Fujikura, Hiroaki Shiohara, Bioorganic & Medicinal Chemistry Pharmaceutical ScienceBiochemistryMedicineDiabetesGlycobiology	2012	19
Design, synthesis, and structure–activity relationships of a series of 4-benzyl-5-isopropyl-1H-pyrazol-3-yl β-d-glycopyranosides substituted with novel hydrophilic groups as highly potent inhibitors of sodium glucose co-transporter 1 (SGLT1) Nobuhiko Fushimi, Hirotaka Teranishi, Kazuo Shimizu, Bioorganic & Medicinal Chemistry Medicinal ChemistryBiochemistryMedicineNovel Hydrophilic GroupsNatural Sciences	2012	15

Page 1